Tom Powles/X
Jul 1, 2025, 19:28
Tom Powles on Final Analysis of the Last 1st-Line Combination Trials in Metastatic Clear Cell RCC
Tom Powles, Head of Solid Tumor Research at Barts Cancer Institute, shared a post on X:
“With the final analysis of the last of the 1st line metastatic clear cell RCC trials combination trials it’s still fair to say ‘pick one and use it well’.
GUARD Symposium 2025 Ipi/nivo is less good at getting initial control but has less long-term toxicity.”
More posts featuring Tom Powles on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 3, 2025, 13:19
Jul 3, 2025, 12:37
Jul 3, 2025, 12:18
Jul 3, 2025, 11:56
Jul 3, 2025, 11:29
Jul 3, 2025, 10:55